161 related articles for article (PubMed ID: 30836651)
1. Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer.
Humayun-Zakaria N; Arnold R; Goel A; Ward D; Savill S; Bryan RT
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30836651
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
[TBL] [Abstract][Full Text] [Related]
3. Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.
Tang HY; Beer LA; Tanyi JL; Zhang R; Liu Q; Speicher DW
J Proteomics; 2013 Aug; 89():165-78. PubMed ID: 23792823
[TBL] [Abstract][Full Text] [Related]
4. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Earl J; Rico D; Carrillo-de-Santa-Pau E; Rodríguez-Santiago B; Méndez-Pertuz M; Auer H; Gómez G; Grossman HB; Pisano DG; Schulz WA; Pérez-Jurado LA; Carrato A; Theodorescu D; Chanock S; Valencia A; Real FX
BMC Genomics; 2015 May; 16(1):403. PubMed ID: 25997541
[TBL] [Abstract][Full Text] [Related]
5. Developmental expression of high molecular weight tropomyosin isoforms in Mesocestoides corti.
Koziol U; Costábile A; Domínguez MF; Iriarte A; Alvite G; Kun A; Castillo E
Mol Biochem Parasitol; 2011 Feb; 175(2):181-91. PubMed ID: 21093500
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of skeletal muscle myosin-II and brush border myosin-I enzymology and mechanochemistry by bacterially produced tropomyosin isoforms.
Fanning AS; Wolenski JS; Mooseker MS; Izant JG
Cell Motil Cytoskeleton; 1994; 29(1):29-45. PubMed ID: 7820856
[TBL] [Abstract][Full Text] [Related]
7. The impact of tropomyosins on actin filament assembly is isoform specific.
Janco M; Bonello TT; Byun A; Coster AC; Lebhar H; Dedova I; Gunning PW; Böcking T
Bioarchitecture; 2016 Jul; 6(4):61-75. PubMed ID: 27420374
[TBL] [Abstract][Full Text] [Related]
8. Structure and evolution of tropomyosin genes.
Vrhovski B; Thézé N; Thiébaud P
Adv Exp Med Biol; 2008; 644():6-26. PubMed ID: 19209810
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
10. [Role of tropomyosin isoforms in diversification of actin filaments functions].
Moraczewska J
Postepy Biochem; 2009; 55(2):201-6. PubMed ID: 19824477
[TBL] [Abstract][Full Text] [Related]
11. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.
Liu X; Yao D; Liu C; Cao Y; Yang Q; Sun Z; Liu D
Tumour Biol; 2016 Jun; 37(6):8367-74. PubMed ID: 26733163
[TBL] [Abstract][Full Text] [Related]
13. Clinical and RNA expression integrated signature for urothelial bladder cancer prognosis.
Xiong J; Xiong K; Bing Z
Cancer Biomark; 2018 Feb; 21(3):535-546. PubMed ID: 29226853
[TBL] [Abstract][Full Text] [Related]
14. Myosin motor isoforms direct specification of actomyosin function by tropomyosins.
Clayton JE; Pollard LW; Murray GG; Lord M
Cytoskeleton (Hoboken); 2015 Mar; 72(3):131-45. PubMed ID: 25712463
[TBL] [Abstract][Full Text] [Related]
15. Metallothionein isoform 3 as a potential biomarker for human bladder cancer.
Sens MA; Somji S; Lamm DL; Garrett SH; Slovinsky F; Todd JH; Sens DA
Environ Health Perspect; 2000 May; 108(5):413-8. PubMed ID: 10811567
[TBL] [Abstract][Full Text] [Related]
16. Expression of tropomyosins in lung cancer - a potential role in carcinogenesis and its utility in a histopathological diagnosis.
Okudela K; Mitsui H; Woo T; Kojima Y; Matsumura M; Arai H; Suzuki T; Umeda S; Tateishi Y; Saito Y; Tajiri M; Masuda M; Kameda Y; Ohashi K
Histol Histopathol; 2016 Aug; 31(8):857-66. PubMed ID: 26750107
[TBL] [Abstract][Full Text] [Related]
17. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor tropomyosin Tpm2.1 regulates sensitivity to apoptosis beyond anoikis characterized by changes in the levels of intrinsic apoptosis proteins.
Desouza-Armstrong M; Gunning PW; Stehn JR
Cytoskeleton (Hoboken); 2017 Jun; 74(6):233-248. PubMed ID: 28378936
[TBL] [Abstract][Full Text] [Related]
19. SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer.
Mukherjee N; Cardenas E; Bedolla R; Ghosh R
Oncotarget; 2017 Feb; 8(9):15114-15125. PubMed ID: 28122346
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis for tropomyosin isoform diversity.
Lees-Miller JP; Helfman DM
Bioessays; 1991 Sep; 13(9):429-37. PubMed ID: 1796905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
